SCHEMBL30917697

SCHEMBL30917697

CC1CCC(=O)c2cc(Br)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.44
CYP1A2 P05177 1/20 0.40
MAPK1 P28482 1/20 0.40
SRD5A1 P18405 1/20 0.38
S100A4 P26447 1/20 0.38
EDNRB P24530 2/20 0.38
EDNRA P25101 2/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
PARP10 Q53GL7 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PARP1 P09874 1/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
PTPRC P08575 1/20 0.34
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31650648 1.00 PBRM1 (0.44) PBRM1CYP1A2MAPK1SRD5A1S100A4
SCHEMBL30917701 1.00 PBRM1 (0.44) PBRM1CYP1A2MAPK1SRD5A1S100A4
SCHEMBL8617679 1.00 PBRM1 (0.44) PBRM1CYP1A2MAPK1SRD5A1S100A4
Aluminum Chloride Anhydrous SCHEMBL30917821 0.94 PBRM1 (0.40) PBRM1CYP1A2MAPK1SRD5A1S100A4
Aluminum Chloride Anhydrous SCHEMBL31737384 0.94 PBRM1 (0.40) PBRM1CYP1A2MAPK1SRD5A1S100A4
SCHEMBL14169119 0.82 PBRM1 (0.54) PBRM1CYP1A2MAPK1S100A4EDNRB
SCHEMBL26656332 0.82 PBRM1 (0.54) PBRM1CYP1A2MAPK1S100A4EDNRB
SCHEMBL13383481 0.81 ACHE (0.46) SRD5A1PARP10PARP1CA1CA2
SCHEMBL28045673 0.81 ACHE (0.46) SRD5A1PARP10PARP1CA1CA2
SCHEMBL31650145 0.80 PBRM1 (0.39) PBRM1CYP1A2MAPK1SRD5A1S100A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022132-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS TREELINE BIOSCIENCES INC (US) 2026-01-22 US disclosed
EP-4622716-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2025-10-01 EP disclosed
WO-2025038936-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2025-02-20 WO disclosed
WO-2024112654-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2024-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022132-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS KRAS, NRAS, G3BP2 PBRM1 1422/4885CYP1A2 2265/4885MAPK1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.